Gastric Cancer, Gastroesophageal-junction Cancer
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. The primary study hypotheses are that: Neoadjuvant and adjuvant Tislelizumab plus chemoradiotherapy, followed by adjuvant Tislelizumab and chemotherapy is superior to neoadjuvant chemoradiotherapy or chemotherapy, followed by adjuvant chemotherapy in terms of rate of Pathological Complete Response (pathCR) at the time of surgery.
Interventions
DRUGTislelizumab
IV infusion
DRUGS-1
Oral tablets
DRUGOxaliplatin
IV infusion
DRUGNab paclitaxel
IV infusion
RADIATIONRadiation
TOMO/VMAT
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3\ 4aN+M0 or T4bNanyM0 （AJCC Version 8） 2. Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 3. Has adequate organ function. 4. Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy. 5. Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater.
Exclusion criteria
1. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that have undergone potentially curative therapy are not excluded. 2. Has received prior systemic anti-cancer therapy including investigational agents for the current malignancy. 3. Has an active infection requiring systemic therapy. 4. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis. 5. Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. 6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior the first dose of study treatment. 7. Has an active autoimmune disease that has required systemic treatment in past 2 years. 8. Has a known history of human immunodeficiency virus (HIV) infection. 9. Has a known history of Hepatitis B or known active Hepatitis C virus infection (HBsAg positive with HBV DNA≥500 IU/ml；HCV：HCV antigen positive with HCV copies \>ULN). 10. Has had an allogenic tissue/solid organ transplant. 11. Has received a live vaccine within 30 days prior to the first dose of study treatment. 12. Female participants who are breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological Complete Response (pathCR) Rate | Up to approximately 22 weeks | PathCR rate is defined as the percentage of participants having a pathCR. pathCR is defined as no invasive disease within an entirely submitted and evaluated gross lesion, and histologically negative nodes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Up to approximately 2 years | EFS is based on RECIST 1.1 as assessed by the investigator and is defined as the time from randomization to the first of the following events: radiographic disease progression per RECIST 1.1; local or distant recurrence as assessed by CT scan or biopsy if indicated (for participants who are disease free after surgery); clinical progression as evidenced by peritoneal carcinomatosis confirmed by preoperative laparoscopy or laparotomy (for participants who are confirmed to be free of peritoneal involvement by laparoscopy at screening); or death due to any cause. A second primary malignancy, or radiographic progressive disease (PD) during the neoadjuvant phase that does not preclude successful surgery (i.e., disease free after surgery), are not considered EFS events. |
| Overall Survival (OS) | Up to approximately 2 years | OS is defined as the time from randomization to death due to any cause. |
Countries
China
Contacts
Primary ContactJia Wei, MD
Outcome results
None listed